U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C14H20N2O2
Molecular Weight 248.3208
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PINDOLOL

SMILES

CC(C)NCC(O)COC1=CC=CC2=C1C=CN2

InChI

InChIKey=JZQKKSLKJUAGIC-UHFFFAOYSA-N
InChI=1S/C14H20N2O2/c1-10(2)16-8-11(17)9-18-14-5-3-4-13-12(14)6-7-15-13/h3-7,10-11,15-17H,8-9H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C14H20N2O2
Molecular Weight 248.3208
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment: Description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/2879589 http://www.ncbi.nlm.nih.gov/pubmed/6125094 https://www.ncbi.nlm.nih.gov/pubmed/9536453 https://www.ncbi.nlm.nih.gov/pubmed/2429847 http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018285s034lbl.pdf

Pindolol was developed at Sandoz at 1960s. Pindolol is a nonselective beta-adrenergic antagonist (beta-blocker) which possesses intrinsic sympathomimetic activity (partial agonist activity) in therapeutic dosage ranges but does not possess quinidine-like membrane stabilizing activity. The partial beta-adrenergic agonistic activity of pindolol in the heart appears to be completely restricted to the sinoatrial pacemaker. In standard pharmacologic tests in man and animals, Pindolol attenuates increases in heart rate, systolic blood pressure, and cardiac output resulting from exercise and isoproterenol administration, thus confirming its beta-blocking properties. In addition to beta-adrenergic activity pindolol demonstrates mixed agonist-antagonist activity at central 5-HT receptors. Although in accordance with the hypothesis that pindolol increases the antidepressant effects of selective serotonin reuptake inhibitors by antagonism of 5-HT at inhibitory 5-HT1A autoreceptors, pindolol possesses partial agonist activity at 5-HT1A receptors. Pindolol tablets are indicated in the management of hypertension.

Originator

Sources: Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development. Takuji Hara. Edward Elgar Publishing, 2003. ISBN 1843760509 p.76

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
6.4 nM [Ki]
9.25 null [pKd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VISKEN

Approved Use

Pindolol tablets are indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.

Launch Date

3.99859188E11
Primary
PINDOLOL

Approved Use

Pindolol tablets are indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic.

Launch Date

7.1539202E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
250 nM
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PINDOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1200 nM × h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PINDOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
3.1 h
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
PINDOLOL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Other AEs: Bizarre dreams, Dizziness...
Other AEs:
Bizarre dreams (5%)
Dizziness (9%)
Fatigue (8%)
Hallucinations (<1%)
Insomnia (10%)
Nervousness (7%)
Weakness (4%)
Paresthesia (3%)
Dyspnea (5%)
Edema (6%)
Heart failure (<1%)
Palpitations (<1%)
Chest pain (3%)
Joint pain (7%)
Muscle cramps (3%)
Muscle pain (10%)
Abdominal discomfort (4%)
Nausea (5%)
Pruritus (1%)
Rash (<1%)
Anxiety (uncertain, <2%)
Lethargy (uncertain, <2%)
Visual disturbances (uncertain, <2%)
Hyperhidrosis (uncertain, <2%)
Bradycardia (uncertain, <2%)
Claudication (uncertain, <2%)
Cold extremities (uncertain, <2%)
Heart block (uncertain, <2%)
Syncope (uncertain, <2%)
Tachycardia (uncertain, <2%)
Weight gain (uncertain, <2%)
Hypotension (uncertain, <2%)
Diarrhea (uncertain, <2%)
Vomiting (uncertain, <2%)
Wheezing (uncertain, <2%)
Impotence (uncertain, <2%)
Pollakiuria (uncertain, <2%)
Eye discomfort (uncertain, <2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Pruritus 1%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Insomnia 10%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Muscle pain 10%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Chest pain 3%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Muscle cramps 3%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Paresthesia 3%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Abdominal discomfort 4%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Weakness 4%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Bizarre dreams 5%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Dyspnea 5%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Nausea 5%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Edema 6%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Joint pain 7%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Nervousness 7%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Fatigue 8%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Dizziness 9%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Hallucinations <1%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Heart failure <1%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Palpitations <1%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Rash <1%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Anxiety uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Bradycardia uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Claudication uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Cold extremities uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Diarrhea uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Eye discomfort uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Heart block uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Hyperhidrosis uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Hypotension uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Impotence uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Lethargy uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Pollakiuria uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Syncope uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Tachycardia uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Visual disturbances uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Vomiting uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Weight gain uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Wheezing uncertain, <2%
5 mg 2 times / day steady, oral (starting)
Recommended
Dose: 5 mg, 2 times / day
Route: oral
Route: steady
Dose: 5 mg, 2 times / day
Sources:
unhealthy
Health Status: unhealthy
Condition: Hypertension
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer




Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
yes
yes
yes (co-administration study)
Comment: cimetidine coadministration increases pindolol plasma levels
yes
yes (co-administration study)
Comment: cimetidine increased AUC by 1.4 fold and Cmax by 1.3 fold
yes
yes (co-administration study)
Comment: cimetidine increased AUC by 1.4 fold and Cmax by 1.3 fold
PubMed

PubMed

TitleDatePubMed
Effects of prindolol on isoproterenol-induced subendocardial ischaemia in dogs with multiple chronic coronary artery occlusion.
1975 Jul
Roles of 5-HT receptors in the release and action of secretin on pancreatic secretion in rats.
2001 Apr
Flesinoxan, a 5-HT1A receptor agonist/alpha 1-adrenoceptor antagonist, lowers intraocular pressure in NZW rabbits.
2001 Aug
Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low.
2001 Dec
(+/-)-Pindolol acts as a partial agonist at atypical beta-adrenoceptors in the guinea pig duodenum.
2001 Jan
The antidepressant activity of inositol in the forced swim test involves 5-HT(2) receptors.
2001 Jan 8
An investigation of the mechanisms responsible for acute fluoxetine-induced anxiogenic-like effects in mice.
2001 Jun
Quantifying drug-related 5-HT1A receptor occupancy with.
2001 May
Trimetazidine for stable angina pectoris.
2001 May
Sympathomimetic effects of pindolol in depression.
2001 Nov
Influence of tryptophan hydroxylase and serotonin transporter genes on fluvoxamine antidepressant activity.
2001 Sep
Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.
2001 Sep 1
Bopindolol: pharmacological basis and clinical implications.
2001 Spring
[Reactions between dialkylamine drugs, 2,3-dichloro-1,4-naphthoquinone and acetaldehyde].
2002 Aug
Altered expression of autonomic neurotransmitter receptors and proliferative responses in lymphocytes from a chronic mild stress model of depression: effects of fluoxetine.
2002 Aug
Synthesis and evaluation of radiolabeled antagonists for imaging of beta-adrenoceptors in the brain with PET.
2002 Feb
Management of treatment resistant obsessive-compulsive disorder. Algorithms for pharmacotherapy.
2002 Jun
5-HT1A receptor blockade and the motivational profile of ethanol.
2002 Jun 28
Spin trapping study of reactive oxygen species formation during bopindolol peroxidation.
2002 Oct 15
Anxiolytic-like effects of baicalein and baicalin in the Vogel conflict test in mice.
2003 Mar 19
Patents

Sample Use Guides

The recommended initial dose of pindolol tablets is 5 mg b.i.d. alone or in combination with other antihypertensive agents. An antihypertensive response usually occurs within the first week of treatment. Maximal response, however, may take as long as or occasionally longer than 2 weeks. If a satisfactory reduction in blood pressure does not occur within 3 to 4 weeks, the dose may be adjusted in increments of 10 mg/day at these intervals up to a maximum of 60 mg/day.
Route of Administration: Oral
In Vitro Use Guide
Pindolol (1-10 uM) blocked the catecholamine-induced augmentation of late after-discharge (LAD) (postganglionic branches or ganglion cells of the paravertebral sympathetic chain of the bullfrog were used in vitro)
Substance Class Chemical
Created
by admin
on Thu Jul 06 02:10:02 UTC 2023
Edited
by admin
on Thu Jul 06 02:10:02 UTC 2023
Record UNII
BJ4HF6IU1D
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PINDOLOL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
NSC-757276
Code English
4-(2-HYDROXY-3-ISOPROPYLAMINOPROPOXY)INDOLE
Systematic Name English
PINDOLOL COMPONENT OF VISKAZIDE
Common Name English
PINDOLOL [JAN]
Common Name English
PECTOBLOC
Brand Name English
DL-LB-46
Common Name English
(RS)-PINDOLOL
Common Name English
DL-PINDOLOL
Common Name English
2-PROPANOL, 1-(1H-INDOL-4-YLOXY)-3-(1-METHYLETHYL)AMINO-
Systematic Name English
PINDOLOL [MI]
Common Name English
PYNASTIN
Common Name English
PINDOLOL [HSDB]
Common Name English
PINDOLOL [EP MONOGRAPH]
Common Name English
PINDOLOL [USAN]
Common Name English
LB-46
Code English
DECRETEN
Common Name English
4-(3-ISOPROPYLAMINO-2-HYDROXYPROPOXY)INDOLE
Systematic Name English
VISKAZIDE COMPONENT PINDOLOL
Common Name English
1-((1-METHYLETHYL)AMINO)-3-(4-INDOLYLOXY)-2-PROPANOL
Systematic Name English
CARVISKEN
Brand Name English
PINDOLOL [VANDF]
Common Name English
PINBETOL
Common Name English
(±)-PINDOLOL
Common Name English
PRINODOLOL
Common Name English
1-(Indol-4-yloxy)-3-(isopropylamino)-2-propanol
Systematic Name English
PINDOLOL [USP MONOGRAPH]
Common Name English
CALVISKEN
Brand Name English
PINDOLOL [MART.]
Common Name English
GLAUCO-VISKEN
Common Name English
APO-PINDOL
Common Name English
BLOCKLIN-L
Brand Name English
N-(2-HYDROXY-3-(1H-INDOL-4-YLOXY)PROPYL)-N-ISOPROPYLAMINE
Systematic Name English
PINDOLOL [USP-RS]
Common Name English
pindolol [INN]
Common Name English
PINDOLOL [ORANGE BOOK]
Common Name English
DL-4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)INDOLE
Common Name English
Pindolol [WHO-DD]
Common Name English
(±)-4-(2-HYDROXY-3-(ISOPROPYLAMINO)PROPOXY)INDOLE
Systematic Name English
DURAPINDOL
Common Name English
VISKEN
Brand Name English
BETAPINDOL
Common Name English
(±)-LB-46
Code English
2-PROPANOL, 1-(INDOL-4-YLOXY)-3-(ISOPROPYLAMINO)-
Systematic Name English
Classification Tree Code System Code
WHO-VATC QC07AA03
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
LIVERTOX NBK548489
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
NCI_THESAURUS C29576
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
NDF-RT N0000000161
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
WHO-VATC QC07CA03
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
WHO-ATC C07CA03
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
NDF-RT N0000175556
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
WHO-ATC C07AA03
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
Code System Code Type Description
FDA UNII
BJ4HF6IU1D
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
RXCUI
8332
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY RxNorm
CHEBI
8214
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
DRUG BANK
DB00960
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
MESH
D010869
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
EPA CompTox
DTXSID8023476
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
DRUG CENTRAL
2176
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
INN
2698
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
MERCK INDEX
M8824
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY Merck Index
LACTMED
Pindolol
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
NCI_THESAURUS
C47673
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
HSDB
6539
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
SMS_ID
100000092294
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
WIKIPEDIA
PINDOLOL
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
ECHA (EC/EINECS)
236-867-9
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
ChEMBL
CHEMBL500
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
PUBCHEM
4828
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
CAS
13523-86-9
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
EVMPD
SUB09854MIG
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
DAILYMED
BJ4HF6IU1D
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
IUPHAR
91
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
NSC
757276
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
RS_ITEM_NUM
1539701
Created by admin on Thu Jul 06 02:10:02 UTC 2023 , Edited by admin on Thu Jul 06 02:10:02 UTC 2023
PRIMARY
Related Record Type Details
TARGET->PARTIAL AGONIST
ENANTIOMER -> RACEMATE
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
MAJOR
URINE
METABOLITE -> PARENT
MINOR
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
METABOLITE -> PARENT
URINE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC